Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers’. The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGN151 in patients with recurrent endometrial, ovarian, fallopian tube, primary peritoneal, or cervical cancers.
The intervention being tested is IMGN151, an antibody-drug conjugate administered via intravenous infusion every three weeks. This treatment is designed to target and destroy cancer cells in patients who are suitable for nonplatinum single-agent therapy.
The study follows an interventional design with a sequential intervention model, and no masking is involved. The primary purpose is treatment-focused, aiming to assess the potential benefits of IMGN151 in the specified patient population.
The study began on January 11, 2023, with an expected completion date in August 2025. These dates are crucial for tracking the study’s progress and potential market entry of IMGN151.
This study update could positively impact AbbVie’s stock performance by enhancing investor confidence in the company’s oncology pipeline. The successful development of IMGN151 may position AbbVie competitively within the gynaecological cancer treatment market, potentially affecting competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.